• Something wrong with this record ?

Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study

K. Fizazi, G. Kramer, JC. Eymard, CN. Sternberg, J. de Bono, D. Castellano, B. Tombal, C. Wülfing, M. Liontos, J. Carles, R. Iacovelli, B. Melichar, Á. Sverrisdóttir, C. Theodore, S. Feyerabend, C. Helissey, S. Oudard, G. Facchini, EM. Poole, A....

. 2020 ; 21 (11) : 1513-1525. [pub] 20200911

Language English Country Great Britain

Document type Clinical Trial, Phase IV, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc20027695
E-resources Online Full text

NLK ProQuest Central from 2000-09-01 to 2 months ago
Nursing & Allied Health Database (ProQuest) from 2000-09-01 to 2 months ago
Health & Medicine (ProQuest) from 2000-09-01 to 2 months ago
Public Health Database (ProQuest) from 2000-09-01 to 2 months ago

Links

PubMed 32926841
DOI 10.1016/s1470-2045(20)30449-6
Knihovny.cz E-resources

BACKGROUND: In the CARD study, cabazitaxel significantly improved radiographic progression-free survival and overall survival versus abiraterone or enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel and the alternative androgen signalling-targeted inhibitor. Here, we report the quality-of-life outcomes from the CARD study. METHODS: CARD was a randomised, multicentre, open-label, phase 4 study involving 62 clinical sites across 13 European countries. Patients (aged ≥18 years, Eastern Cooperative Oncology Group (ECOG) performance status ≤2) with confirmed metastatic castration-resistant prostate cancer were randomly assigned (1:1) by means of an interactive voice-web response system to receive cabazitaxel (25 mg/m2 intravenously every 3 weeks, 10 mg daily prednisone, and granulocyte colony-stimulating factor) versus abiraterone (1000 mg orally once daily plus 5 mg prednisone twice daily) or enzalutamide (160 mg orally daily). Stratification factors were ECOG performance status, time to disease progression on the previous androgen signalling-targeted inhibitor, and timing of the previous androgen signalling-targeted inhibitor. The primary endpoint was radiographic progression-free survival; here, we present more detailed analyses of pain (assessed using item 3 on the Brief Pain Inventory-Short Form [BPI-SF]) and symptomatic skeletal events, alongside preplanned patient-reported outcomes, assessed using the Functional Assessment of Cancer Therapy-Prostate (FACT-P) questionnaire and the EuroQoL-5 dimensions, 5 level scale (EQ-5D-5L). Efficacy analyses were done in the intention-to-treat population. Pain response was analysed in the intention-to-treat population with baseline and at least one post-baseline assessment of BPI-SF item 3, and patient-reported outcomes (PROs) were analysed in the intention-to-treat population with baseline and at least one post-baseline assessment of either FACT-P or EQ-5D-5L (PRO population). Analyses of skeletal-related events were also done in the intention-to-treat population. The CARD study is registered with ClinicalTrials.gov, NCT02485691, and is no longer enrolling. FINDINGS: Between Nov 17, 2015, and Nov 28, 2018, of 303 patients screened, 255 were randomly assigned to cabazitaxel (n=129) or abiraterone or enzalutamide (n=126). Median follow-up was 9·2 months (IQR 5·6-13·1). Pain response was observed in 51 (46%) of 111 patients with cabazitaxel and 21 (19%) of 109 patients with abiraterone or enzalutamide (p<0·0001). Median time to pain progression was not estimable (NE; 95% CI NE-NE) with cabazitaxel and 8·5 months (4·9-NE) with abiraterone or enzalutamide (hazard ratio [HR] 0·55, 95% CI 0·32-0·97; log-rank p=0·035). Median time to symptomatic skeletal events was NE (95% CI 20·0-NE) with cabazitaxel and 16·7 months (10·8-NE) with abiraterone or enzalutamide (HR 0·59, 95% CI 0·35-1·01; log-rank p=0·050). Median time to FACT-P total score deterioration was 14·8 months (95% CI 6·3-NE) with cabazitaxel and 8·9 months (6·3-NE) with abiraterone or enzalutamide (HR 0·72, 95% CI 0·44-1·20; log-rank p=0·21). There was a significant treatment effect seen in changes from baseline in EQ-5D-5L utility index score in favour of cabazitaxel over abiraterone or enzalutamide (p=0·030) but no difference between treatment groups for change from baseline in EQ-5D-5L visual analogue scale (p=0·060). INTERPRETATION: Since cabazitaxel improved pain response, time to pain progression, time to symptomatic skeletal events, and EQ-5D-5L utility index, clinicians and patients with metastatic castration-resistant prostate cancer can be reassured that cabazitaxel will not reduce quality of life when compared with treatment with a second androgen signalling-targeted inhibitor. FUNDING: Sanofi.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20027695
003      
CZ-PrNML
005      
20210114152235.0
007      
ta
008      
210105s2020 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/S1470-2045(20)30449-6 $2 doi
035    __
$a (PubMed)32926841
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Fizazi, Karim $u Department of Cancer Medicine, Institut Gustave Roussy and University of Paris Saclay, Villejuif, France. Electronic address: karim.fizazi@gustaveroussy.fr.
245    10
$a Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study / $c K. Fizazi, G. Kramer, JC. Eymard, CN. Sternberg, J. de Bono, D. Castellano, B. Tombal, C. Wülfing, M. Liontos, J. Carles, R. Iacovelli, B. Melichar, Á. Sverrisdóttir, C. Theodore, S. Feyerabend, C. Helissey, S. Oudard, G. Facchini, EM. Poole, A. Ozatilgan, C. Geffriaud-Ricouard, S. Bensfia, R. de Wit,
520    9_
$a BACKGROUND: In the CARD study, cabazitaxel significantly improved radiographic progression-free survival and overall survival versus abiraterone or enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel and the alternative androgen signalling-targeted inhibitor. Here, we report the quality-of-life outcomes from the CARD study. METHODS: CARD was a randomised, multicentre, open-label, phase 4 study involving 62 clinical sites across 13 European countries. Patients (aged ≥18 years, Eastern Cooperative Oncology Group (ECOG) performance status ≤2) with confirmed metastatic castration-resistant prostate cancer were randomly assigned (1:1) by means of an interactive voice-web response system to receive cabazitaxel (25 mg/m2 intravenously every 3 weeks, 10 mg daily prednisone, and granulocyte colony-stimulating factor) versus abiraterone (1000 mg orally once daily plus 5 mg prednisone twice daily) or enzalutamide (160 mg orally daily). Stratification factors were ECOG performance status, time to disease progression on the previous androgen signalling-targeted inhibitor, and timing of the previous androgen signalling-targeted inhibitor. The primary endpoint was radiographic progression-free survival; here, we present more detailed analyses of pain (assessed using item 3 on the Brief Pain Inventory-Short Form [BPI-SF]) and symptomatic skeletal events, alongside preplanned patient-reported outcomes, assessed using the Functional Assessment of Cancer Therapy-Prostate (FACT-P) questionnaire and the EuroQoL-5 dimensions, 5 level scale (EQ-5D-5L). Efficacy analyses were done in the intention-to-treat population. Pain response was analysed in the intention-to-treat population with baseline and at least one post-baseline assessment of BPI-SF item 3, and patient-reported outcomes (PROs) were analysed in the intention-to-treat population with baseline and at least one post-baseline assessment of either FACT-P or EQ-5D-5L (PRO population). Analyses of skeletal-related events were also done in the intention-to-treat population. The CARD study is registered with ClinicalTrials.gov, NCT02485691, and is no longer enrolling. FINDINGS: Between Nov 17, 2015, and Nov 28, 2018, of 303 patients screened, 255 were randomly assigned to cabazitaxel (n=129) or abiraterone or enzalutamide (n=126). Median follow-up was 9·2 months (IQR 5·6-13·1). Pain response was observed in 51 (46%) of 111 patients with cabazitaxel and 21 (19%) of 109 patients with abiraterone or enzalutamide (p<0·0001). Median time to pain progression was not estimable (NE; 95% CI NE-NE) with cabazitaxel and 8·5 months (4·9-NE) with abiraterone or enzalutamide (hazard ratio [HR] 0·55, 95% CI 0·32-0·97; log-rank p=0·035). Median time to symptomatic skeletal events was NE (95% CI 20·0-NE) with cabazitaxel and 16·7 months (10·8-NE) with abiraterone or enzalutamide (HR 0·59, 95% CI 0·35-1·01; log-rank p=0·050). Median time to FACT-P total score deterioration was 14·8 months (95% CI 6·3-NE) with cabazitaxel and 8·9 months (6·3-NE) with abiraterone or enzalutamide (HR 0·72, 95% CI 0·44-1·20; log-rank p=0·21). There was a significant treatment effect seen in changes from baseline in EQ-5D-5L utility index score in favour of cabazitaxel over abiraterone or enzalutamide (p=0·030) but no difference between treatment groups for change from baseline in EQ-5D-5L visual analogue scale (p=0·060). INTERPRETATION: Since cabazitaxel improved pain response, time to pain progression, time to symptomatic skeletal events, and EQ-5D-5L utility index, clinicians and patients with metastatic castration-resistant prostate cancer can be reassured that cabazitaxel will not reduce quality of life when compared with treatment with a second androgen signalling-targeted inhibitor. FUNDING: Sanofi.
650    _2
$a senioři $7 D000368
650    _2
$a antagonisté androgenů $x aplikace a dávkování $x škodlivé účinky $7 D000726
650    _2
$a androgeny $x genetika $7 D000728
650    _2
$a androsteny $x aplikace a dávkování $x škodlivé účinky $7 D000736
650    _2
$a přežití bez známek nemoci $7 D018572
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a metastázy nádorů $7 D009362
650    _2
$a fenylthiohydantoin $x aplikace a dávkování $x škodlivé účinky $x analogy a deriváty $7 D010669
650    _2
$a nádory prostaty rezistentní na kastraci $x farmakoterapie $x epidemiologie $x patologie $7 D064129
650    _2
$a kvalita života $7 D011788
650    _2
$a taxoidy $x aplikace a dávkování $x škodlivé účinky $7 D043823
650    _2
$a výsledek terapie $7 D016896
655    _2
$a klinické zkoušky, fáze IV $7 D017429
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Kramer, Gero $u Department of Urology, Medical University of Vienna, Vienna, Austria.
700    1_
$a Eymard, Jean-Christophe $u Institut Jean Godinot, Reims, France.
700    1_
$a Sternberg, Cora N $u Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA.
700    1_
$a de Bono, Johann $u The Institute of Cancer Research and the Royal Marsden Hospital, London, UK.
700    1_
$a Castellano, Daniel $u 12 de Octubre University Hospital, Madrid, Spain.
700    1_
$a Tombal, Bertrand $u Institut de Recherche Clinique, Université Catholique de Louvain, Louvain, Belgium.
700    1_
$a Wülfing, Christian $u Department of Urology, Asklepios Tumorzentrum Hamburg, Asklepios Klinik Altona, Hamburg, Germany.
700    1_
$a Liontos, Michael $u Department of Clinical Therapeutics, Oncology Unit, Alexandra Hospital, Athens, Greece.
700    1_
$a Carles, Joan $u Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.
700    1_
$a Iacovelli, Roberto $u Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy; Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
700    1_
$a Melichar, Bohuslav $u Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic.
700    1_
$a Sverrisdóttir, Ásgerður $u Landspitali University Hospital, Reykjavik, Iceland.
700    1_
$a Theodore, Christine $u Foch Hospital, Suresnes, France.
700    1_
$a Feyerabend, Susan $u Studienpraxis Urologie, Nürtingen, Germany.
700    1_
$a Helissey, Carole $u Hôpital d'Instruction des Armées BÉGIN, Saint Mandé, France.
700    1_
$a Oudard, Stéphane $u Georges Pompidou European Hospital, Paris Descartes University, Paris, France.
700    1_
$a Facchini, Gaetano $u Istituto Nazionale Tumori-IRCCS-Fondazione, Naples, Italy.
700    1_
$a Poole, Elizabeth M $u Sanofi, Global Medical Oncology, Cambridge, MA, USA.
700    1_
$a Ozatilgan, Ayse $u Sanofi, Global Medical Oncology, Cambridge, MA, USA.
700    1_
$a Geffriaud-Ricouard, Christine $u Sanofi, Europe Medical Oncology, Paris, France.
700    1_
$a Bensfia, Samira $u Sanofi, Europe Medical Oncology, Paris, France.
700    1_
$a de Wit, Ronald $u Erasmus Medical Center, Rotterdam, Netherlands.
773    0_
$w MED00011558 $t The Lancet. Oncology $x 1474-5488 $g Roč. 21, č. 11 (2020), s. 1513-1525
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32926841 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20210105 $b ABA008
991    __
$a 20210114152233 $b ABA008
999    __
$a ok $b bmc $g 1608030 $s 1118875
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 21 $c 11 $d 1513-1525 $e 20200911 $i 1474-5488 $m Lancet oncology $n Lancet Oncol. $x MED00011558
LZP    __
$a Pubmed-20210105

Find record

Citation metrics

Archiving options